CRIS Current Research Information System

DE BENEDITTIS, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.150
AS - Asia 3.379
EU - Europa 2.718
AF - Africa 244
SA - Sud America 208
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 5
Totale 10.709
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.111
VN - Vietnam 993
SG - Singapore 900
CN - Cina 732
GB - Regno Unito 713
IT - Italia 424
SE - Svezia 365
DE - Germania 352
HK - Hong Kong 257
FR - Francia 178
IN - India 177
RU - Federazione Russa 151
BR - Brasile 143
NL - Olanda 128
IE - Irlanda 120
TG - Togo 80
JP - Giappone 72
ZA - Sudafrica 70
EE - Estonia 58
JO - Giordania 45
UA - Ucraina 45
CI - Costa d'Avorio 38
BG - Bulgaria 37
FI - Finlandia 34
AR - Argentina 27
CH - Svizzera 27
BD - Bangladesh 23
CA - Canada 23
ID - Indonesia 22
NG - Nigeria 22
PH - Filippine 22
BE - Belgio 20
IQ - Iraq 16
TR - Turchia 16
KR - Corea 14
PL - Polonia 14
PK - Pakistan 12
EC - Ecuador 11
SC - Seychelles 11
TH - Thailandia 11
UZ - Uzbekistan 11
AT - Austria 10
MX - Messico 10
TW - Taiwan 10
ES - Italia 9
IR - Iran 9
VE - Venezuela 8
LB - Libano 7
SA - Arabia Saudita 6
AU - Australia 5
CL - Cile 5
CZ - Repubblica Ceca 5
GR - Grecia 5
MA - Marocco 5
MY - Malesia 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
EU - Europa 4
HR - Croazia 4
QA - Qatar 4
TN - Tunisia 4
AL - Albania 3
AZ - Azerbaigian 3
CR - Costa Rica 3
DZ - Algeria 3
EG - Egitto 3
IL - Israele 3
NO - Norvegia 3
PE - Perù 3
PY - Paraguay 3
BO - Bolivia 2
KZ - Kazakistan 2
PT - Portogallo 2
RO - Romania 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
ET - Etiopia 1
GH - Ghana 1
HN - Honduras 1
HU - Ungheria 1
KE - Kenya 1
LT - Lituania 1
LY - Libia 1
MR - Mauritania 1
MT - Malta 1
MU - Mauritius 1
NP - Nepal 1
PA - Panama 1
RS - Serbia 1
SO - Somalia 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 10.709
Salva come PNG Salva come JPEG
Città #
Southend 648
Singapore 612
Ashburn 443
Fairfield 431
Chandler 416
Hong Kong 243
Houston 212
Ho Chi Minh City 210
Dong Ket 195
Wilmington 194
Woodbridge 189
Seattle 188
San Jose 185
Princeton 152
Beijing 146
Cambridge 139
Hanoi 137
Dublin 120
Bologna 109
Ann Arbor 104
Santa Clara 92
Boardman 86
Lomé 80
Lauterbourg 67
Los Angeles 65
Nanjing 65
Westminster 62
Tokyo 59
New York 58
Padova 52
Amman 45
Da Nang 42
Medford 40
Abidjan 38
Sofia 37
Redmond 33
Bremen 30
Jinan 29
Berlin 28
Helsinki 28
San Diego 28
Shenyang 28
Turin 28
Changsha 27
Dallas 27
Haiphong 27
Redondo Beach 26
Buffalo 25
Hebei 24
Milan 24
Saint Petersburg 24
Guangzhou 22
Abeokuta 20
Bern 20
Frankfurt am Main 20
Jiaxing 20
Munich 20
Nanchang 20
Brussels 19
Florence 16
São Paulo 16
Norwalk 15
Nuremberg 15
Phoenix 15
Mountain View 14
Orem 14
Redwood City 14
Tianjin 14
Biên Hòa 13
Haikou 11
Hải Dương 11
Zhengzhou 11
Forlì 10
Johannesburg 10
Olalla 10
Dearborn 9
Des Moines 9
Falkenstein 9
Hangzhou 9
Jakarta 9
London 9
Shanghai 9
Baghdad 8
Chicago 8
Council Bluffs 8
Montreal 8
Xi'an 8
Bến Tre 7
Can Tho 7
Dhaka 7
Fuzhou 7
Kraków 7
Ningbo 7
Stockholm 7
Toronto 7
Tân Tiến 7
Wuhan 7
Brooklyn 6
Bắc Giang 6
Falls Church 6
Totale 6.958
Salva come PNG Salva come JPEG
Nome #
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 265
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 251
The Heterogeneity of Skewness in T2W-Based Radiomics Predicts the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer 242
Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation 239
Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function 215
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 211
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 208
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 201
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 199
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 194
Classification performance for covid patient prognosis from automatic ai segmentation—a single-center study 185
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 183
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 180
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 179
Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis 178
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 176
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 175
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 171
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 171
Percutaneous abdomino-pelvic abscess drainage in complicated Crohn’s disease 169
Outcomes following percutaneous treatment of biliary stones 166
Best practices in chronic myeloid leukemia monitoring and management 165
Ultra-Deep Sequencing (UDS) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 164
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 160
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 158
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 158
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 157
Portal Hypertensive Biliopathy in Adult Patients: Findings and Interventional Radiologic Treatment--A Single-Center Experience 157
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 156
HIGH RATE OF COMPLETE HEMATOLOGICAL RESPONSE IN ELDERLY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY INNOVATIVE SEQUENTIAL USE OF NILOTINIB AND IMATINIB: A GIMEMA CLINICAL TRIAL LAL 1408 154
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 153
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 153
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 153
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 150
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 150
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 146
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 145
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 144
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 141
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 140
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse 138
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 138
Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era 138
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 138
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 137
Percutaneous management of postoperative Bile leak after hepato-pancreato-biliary surgery: a multi-center experience 136
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 134
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 134
Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients 134
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 134
Diagnostic Accuracy of North America Expert Consensus Statement on Reporting CT Findings in Patients Suspected of Having COVID-19 Infection: An Italian Single-Center Experience 131
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 130
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 129
Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage 129
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 126
Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case 125
Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies 125
Ultradeep-Amplicon Pyrosequencing for Mutation Detection in the Kinase Domain of BCR-ABL Revealed Artificial Low-Level Variants That Need to Be Avoided for Relevant Mutational Data Interpretation 125
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 123
Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant) 122
The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis 120
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 120
Present and future of molecular monitoring in chronic myeloid leukaemia. 118
Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor 118
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 117
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase 114
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia 113
Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2nd-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement 112
Deep sequencing of the bcr-abl kinase domain reveals a high frequency of bcr-abl35-ins insertion/truncation mutation in chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia patients 110
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement 108
You have accessClinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters 97
Totale 10.935
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.065
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.065
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021457 0 0 0 0 0 0 0 0 0 59 46 352
2021/20221.360 122 27 73 94 131 79 16 108 73 83 304 250
2022/20231.579 165 245 70 215 117 116 55 100 295 29 120 52
2023/2024367 19 74 19 30 31 98 14 10 28 10 9 25
2024/20251.335 64 218 141 97 191 61 83 52 16 159 32 221
2025/20262.987 229 183 275 145 391 177 398 137 785 267 0 0
Totale 10.935